Adial granted a 180 calendar day extension by Nasdaq to regain compliance

Adial Pharmaceuticals (ADIL) announced that it has been granted a 180 calendar day extension from The Nasdaq Stock Market to regain compliance with the Nasdaq’s minimum $1.00 bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on Nasdaq, following the expiration of the initial 180 calendar day period to regain compliance on September 1, 2025, which was initially granted on March 5, 2025. The Company now has until March 2, 2026 to meet the Minimum Bid Price Requirement set forth in Nasdaq Listing Rule 5550(a)(2).